[Action of bisphosphonates on malignant osteolysis].

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Presse medicale

• Publication date

  1999-09-25

• Fields of study

  Medicine

• Identifiers
  PMID 10526564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rationale for the use of alendronate in osteoporosis

  2005cited by this paper
• Mechanisms of bone metastasis

  1997cited by this paper
• Loud, sad or bad: young people's perceptions of peer groups and smoking.

  1997cited by this paper
• Parathyroid hormone‐related protein and hypercalcemia

  1997cited by this paper
• Overview of bisphosphonates

  1997cited by this paper
• Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

  1997cited by this paper
• Parathyroid hormone‐related protein and bone metastases

  1997cited by this paper
• Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

  1996cited by this paper
• Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

  1996cited by this paper
• Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development

  1996cited by this paper
• Clodronate decreases the frequency of skeletal metastases in women with breast cancer.

  1996cited by this paper
• Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

  1996cited by this paper
• Bisphosphonates: mechanisms of action.

  1996cited by this paper
• Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.

  1995cited by this paper
• Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

  1994cited by this paper
• Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

  1994cited by this paper
• Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound

  1994cited by this paper
• Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system

  1994cited by this paper
• Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

  1993cited by this paper
• Palliative pamidronate treatment in patients with bone metastases from breast cancer.

  1993cited by this paper
• Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.

  1993cited by this paper
• Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

  1992cited by this paper
• Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.

  1991cited by this paper
• Bisphosphonates

  1991cited by this paper
• Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

  1988cited by this paper
• Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.

  1987cited by this paper
• Treatment of the hypercalcaemia of malignancy with intravenous clodronate.

  1987cited by this paper
• Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.

  1982cited by this paper
• Inhibition by two diphosphonates of bone lysis in tumor-conditioned media.

  1981cited by this paper
• Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.

  1981cited by this paper
• Direct resorption of bone by human breast cancer cells in vitro

  1978cited by this paper

• No citing papers are available for this paper.